Neuropathy News and Research

RSS

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.

11 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

Vibrating device aids diabetic neuropathy foot screening

A small disposable vibrating device may help detect peripheral sensory neuropathy in patients with diabetes, say UK researchers who believe the gadget could replace tuning fork screening.

8 Jun 2012

New study into pain associated with diabetes

Researchers in Sheffield have been awarded over £310,000 to carry out a study that could help revolutionise the way clinicians treat the pain experienced by thousands of people with diabetes.

8 Jun 2012

dSarm/Sarm1 gene promotes axon destruction after injury

Degeneration of the axon and synapse, the slender projection through which neurons transmit electrical impulses to neighboring cells, is a hallmark of some of the most crippling neurodegenerative and brain diseases such as amyotrophic lateral sclerosis (ALS), Huntington's disease and peripheral neuropathy.

8 Jun 2012

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Aeterna Zentaris Inc. today announced that Phase 1 trial results for the Company's oral anticancer compound, perifosine, in multiple myeloma, have been published in the online May 2012 issue of the British Journal of Haematology.

6 Jun 2012

Three-drug regimen provides rapid, durable responses for multiple myeloma

A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Pituitary tumors may lead to glaucomatous changes

Certain tumors of the pituitary gland are associated with glaucomatous abnormalities of the optic nerve head, such as enlarged beta zone, an international research team reports.

30 May 2012

NIH Consortium selects UBM among 11 CoEPEs

With more Americans than ever living with chronic pain, the National Institutes of Health (NIH) Pain Consortium wants the University of Maryland, Baltimore (UMB) and 10 other health professional schools to teach the next generation of health care providers to be better equipped to manage and treat such patients.

25 May 2012

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Pfizer Inc. announced today that the United States Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted on Pfizer's clinical data package for tafamidis meglumine.

25 May 2012

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Insight into why diabetics suffer from increased pain and temperature sensitivity

Why diabetics suffer from increased pain and temperature sensitivity is a step closer to being understood and effectively treated.

17 May 2012

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

11 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Neuropathy News and Research

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

Vibrating device aids diabetic neuropathy foot screening

New study into pain associated with diabetes

dSarm/Sarm1 gene promotes axon destruction after injury

Aeterna Zentaris announces results from perifosine Phase 1 trial on multiple myeloma

Three-drug regimen provides rapid, durable responses for multiple myeloma

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Pituitary tumors may lead to glaucomatous changes

NIH Consortium selects UBM among 11 CoEPEs

FDA advisory committee votes in favor of Pfizer's tafamidis meglumine

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Insight into why diabetics suffer from increased pain and temperature sensitivity

Final results from Alnylam’s ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News